Search results
Showing 181 to 195 of 352 results for eq-5d
Alectinib for untreated ALK-positive advanced non-small-cell lung cancer (TA536)
Evidence-based recommendations on alectinib (Alecensa) for untreated anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer in adults.
Show all sections
Evidence-based recommendations on ruxolitinib (Jakavi) for treating acute graft versus host disease that has an inadequate response to corticosteroids in people 12 years and over.
Show all sections
Evidence-based recommendations on relugolix–estradiol–norethisterone acetate (Ryeqo) for treating moderate to severe symptoms of uterine fibroids in adults of reproductive age.
Omalizumab for previously treated chronic spontaneous urticaria (TA339)
Evidence-based recommendations on omalizumab (Xolair) for treating severe chronic spontaneous urticaria in people of 12 and over.
Evidence-based recommendations on trifluridine–tipiracil (Lonsurf) for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma in adults after 2 or more treatments.
Evidence-based recommendations on colistimethate sodium (Colobreathe) and tobramycin (TOBI Podhaler) dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis in people of 6 years and over.
Nintedanib for treating idiopathic pulmonary fibrosis (TA379)
Evidence-based recommendations on nintedanib (Ofev) for adults with idiopathic pulmonary fibrosis.
Evidence-based recommendations on atezolizumab (Tecentriq) for untreated extensive-stage small-cell lung cancer in adults.
Evidence-based recommendations on quizartinib (Vanflyta) for induction, consolidation and maintenance treatment of newly diagnosed FLT3-ITD-positive acute myeloid leukaemia in adults.
Selinexor with bortezomib and dexamethasone for previously treated multiple myeloma (TA974)
Evidence-based recommendations on selinexor (Nexpovio) with bortezomib and dexamethasone for previously treated multiple myeloma in adults.
Dimethyl fumarate for treating relapsing‑remitting multiple sclerosis (TA320)
Evidence-based recommendations on dimethyl fumarate (Tecfidera) for treating relapsing-remitting multiple sclerosis in adults.
Relugolix–estradiol–norethisterone for treating symptoms of endometriosis (TA1057)
Evidence-based recommendations on relugolix–estradiol–norethisterone (Ryeqo) for treating symptoms of endometriosis in adults of reproductive age.
Show all sections
Lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and over (TA986)
Evidence-based recommendations on lebrikizumab (Ebglyss) for treating moderate to severe atopic dermatitis in people 12 years and over.
Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma (TA720)
Evidence-based recommendations on chlormethine gel (Ledaga) for treating early-stage mycosis fungoides-type cutaneous T-cell lymphoma in adults.
Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer (TA403)
Evidence-based recommendations on ramucirumab (Cyramza) for locally advanced or metastatic non-small-cell lung cancer in adults who have had platinum-based chemotherapy.